8
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Emergency department visits and readmissions after COVID-19 hospitalization: a cross-sectional analysis

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear Editor, Beginning with its first documented case in January 2020, the COVID-19 pandemic has affected tens of millions of people across the world [1] and has necessitated changes in how health systems deliver care to patients. Understanding the anticipated clinical trajectory and healthcare utilization pattern for patients who have contracted this illness is necessary for preparation and coordination at the system level. In this report, we review patients with COVID-19 discharged from two hospitals in the Seattle area during its early initial outbreak and aim to (1) describe the time course of emergency department (ED) encounter and/or rehospitalization after discharge, (2) delineate reasons for the revisit, and (3) identify differences between patients with and without revisits at the individual and system level. Washington State was the initial site of identified COVID-19 spread in the US [2] and a focal point for COVID-19 nationally during the early phase of the pandemic. King County, which includes the city of Seattle, experienced a COVID-19 outbreak in early-mid 2020 with peak daily new diagnoses on April 1, 2020 [3]. The study setting involves two hospitals, both of which are academic teaching centers and share an electronic medical record. One is a 570-bed quaternary hospital and the other a 413-bed county hospital/level 1 trauma center. The catchment area for both includes referrals from the surrounding five-state region. COVID-19 testing strategy at our institution was initially symptom-based but switched to universal testing for all admitted patients on April 13, 2020. We reviewed consecutive discharges in which patients had a laboratory-confirmed SARS-CoV2 result and were discharged alive between February 28, 2020 and May 13, 2020. Patients under the age of 18 years old, pregnant patients, and those who died prior to discharge were excluded (Supplemental Fig. 1). The primary outcome of interest (which we have termed a “revisit”) is an ED encounter or rehospitalization within 30 days after discharge. Encounters for planned procedures were not counted as revisits. Trained research assistants reviewed patient records to collect patient demographics, Charlson Comorbidity Index score, and hospitalization details. Presentation at both index hospitalization and revisit was coded as “directly related to COVID-19” if documented as such in the physician notes and/or if the patient presented with symptoms and timeframe consistent with CDC guidelines [4]. Reasons for presentation not directly related to COVID-19 were also recorded. A standardized REDCap survey tool [5] was used to collect the data. Approval was provided by the University of Washington Institutional Review Board. Normally distributed variables are summarized as means with 95% confidence intervals (95% CI) and comparisons between groups were made using two-sided t tests. Non-normally distributed variables are summarized as medians with interquartile range (IQR) and comparisons between groups were made using Wilcoxon rank-sum test. Categorical variables are presented as counts with percentages and comparisons between groups were made using Fisher’s exact test. Statistical significance is defined as p < 0.05. Any missing data points are noted. Data were analyzed in Stata version 15.1 (College Station, TX). Of 151 index COVID-19 discharges, 36 (24%) returned to the hospital during the study follow-up time period. The 7-day revisit rate was 11% (11 revisits to ED; 6 hospital readmissions), the 14-day revisit rate was 14% (14 revisits to ED; 7 hospital readmissions), and the 30-day revisit rate was 24% (20 revisits to ED; 16 hospital readmissions). In total, revisits occurred a median of 9 days (IQR 3.5–18.5) after discharge. These data are presented in Table 1. Table 1 Frequency and time course of revisits All revisits By type of revisit ED-only Hospital readmission Time course of revisit, n (%)  7-day 17 (11%) 11 (7%) 6 (4%)  14-day 21 (14%) 14 (9%) 7 (5%)  30-day 36 (24%) 20 (13%) 16 (11%) Median time to revisit, days (IQR) 9 (3.5–18.5) 7 (3.5–16) 15 (3–26) Data presented as a percentage of all eligible discharges (n = 151) Patients in this cohort averaged 59.6 years old and were predominantly male (n = 88, 58%). The most commonly represented racial/ethnic groups included White/non-Hispanic (n = 62, 41%), Hispanic/Latino (n = 37, 25%), Asian (n = 22, 15%), and Black/African American (n = 18, 12%), and the most commonly spoken primary languages were English (n = 94, 62%) and Spanish (n = 31, 21%). The median Charlson Comorbidity Index score was 3 (IQR 1–5). A total of 60 (40%) patients were diagnosed with COVID-19 a median of 5 days (IQR 3–8) prior to index hospitalization. No statistically significant difference was noted by patient characteristics or COVID-19 diagnostic details when comparing revisit versus non-revisit groups. These data are presented in Table 2. Table 2 Comparison of revisit vs no revisit groups by patient characteristics, COVID-19 diagnostic details, and index hospitalization outcomes Total N = 151 Revisit N = 36 No revisit N = 115 P Patient characteristics  Age, mean (95% CI) 59.6 (56.8–62.4) 60.6 (54.6–66.5) 59.3 (56.1–62.5) NS Sex, n (%) NS  Female 63 (42%) 12 (33%) 51 (44%)  Male 88 (58%) 24 (67%) 64 (57%) Race/ethnicity, n (%), 1 value missing NS  White, non-Hispanic 62 (41%) 12 (33%) 50 (44%)  Hispanic/Latino 37 (25%) 9 (25%) 28 (25%)  Asian 22 (15%) 5 (14%) 17 (15%)  Black/African American 18 (12%) 8 (22%) 10 (9%)  American Indian/Alaska Native 3 (2%) 2 (6%) 1 (1%)  Native Hawaiian/Pacific Islander 3 (2%) 0 (0%) 3 (3%)  Multiple races 5 (3%) 0 (0%) 5 (4%) Primary language, n (%) NS  English 94 (62%) 20 (56%) 74 (64%)  Spanish 31 (21%) 7 (19%) 24 (21%)  Other 26 (17%) 9 (25%) 17 (15%) Charlson comorbidity index, median (IQR) 3 (1–5) 3 (1.5–6) 3 (1–5) NS COVID-19 diagnostic details  Diagnosed prior to hospitalization, n (%) 60 (40%) 15 (42%) 45 (39%) NS  Median time between diagnosis and hospitalization, days (IQR) 5 (3–8) 5 (1–7) 5 (3–8) NS Index hospitalization outcomes  Reason for index hospitalization directly related to COVID-19, n (%) 114 (75%) 19 (53%) 95 (83%) 0.001  Length of stay, median (IQR) 6 (3–13) 4 (2–10.5) 7 (3–15) 0.047  Transfer to ICU, n (%) 44 (29%) 8 (22%) 36 (31%) NS  Clearance from isolation precautions, n (%) 26 (17%) 6 (17%) 20 (17%) NS Discharge location, n (%) 0.031  Independent living/stable housing 99 (66%) 22 (61%) 77 (67%)  Independent living/unstable housing* 19 (13%) 9 (25%) 10 (9%)  Institutional setting** 33 (22%) 5 (14%) 28 (24%) *Independent living/unstable housing includes discharge to street, vehicle, medical respite center, homeless shelter, or transitional COVID-19 homeless shelter **Institutional setting includes discharge to skilled nursing facility, adult family home, assisted living facility, inpatient rehabilitation, psychiatric facility, or jail/prison NS Non-significant, p ≥ 0.05 Fewer patients were admitted at their index hospitalization for reasons directly related to COVID-19 in the revisit group as compared to the non-revisit group (53 vs 83%, p = 0.001). Patients in the revisit group had a shorter length of stay than the non-revisit group (median 4 days [IQR 2–10.5] vs 7 days [IQR 3–15], p = 0.047). Discharge location also differed by revisit vs non-revisit group (independent living/stable housing: 61 vs 67%; independent living/unstable housing: 2 vs 9%; institutional setting: 14 vs 24%; p = 0.031). A total of 44 (29%) patients spent time in the intensive care unit at some point during hospitalization. Only 26 (17%) patients were cleared from COVID-19 and had infection precautions lifted prior to discharge. No statistically significant difference between revisit vs non-revisit groups was noted for these variables. Of all revisits, half (n = 18, 50%) were directly related to worsening COVID-19 symptoms. In both ED-only revisits and hospital readmissions, individuals presented for other medical issues not directly related to COVID-19 including fall/trauma, CVA/TIA, hematologic/oncologic issues, and non-stroke neurologic issues. Additionally, patients revisited the ED for pain, psychiatric issues, and substance use-related (intoxication/withdrawal) issues and were readmitted to the hospital for acute renal failure. This information is presented in Table 3. Table 3 Reasons for revisit All revisits N = 36 ED-only N = 20 Hospital readmission N = 16 Symptoms directly related to COVID-19, n (%) 18 (50%) 8 (40%) 10 (63%) Non-COVID-19 medical concern, n (%) 18 (50%) 12 (60%) 6 (38%) Fall/trauma 5 4 1 CVA/TIA 2 1 1 Hematologic/oncologic issue 2 1 1 Neurologic issue, non-stroke 2 1 1 GI issue 2 2 0 Acute renal failure 2 0 2 Pain, cause unspecified 1 1 0 Psychiatric issue 1 1 0 Substance use-related (intoxication/withdrawal) 1 1 0 In conclusion, we found that nearly a quarter of patients with COVID-19 who discharged during the study time period had a revisit (either ED encounter or rehospitalization) within 30 days of discharge. These patients had a shorter index hospital length of stay and a higher proportion of discharge to unstable housing than patients without a revisit. Our 30-day hospital readmission rate of 11% is higher than most reported comparisons both in the US (2.2% overall readmission rate in New York City [6], 6.8% 30-day hospital readmission in Rhode Island [7], 10.3% overall hospital readmission in Boston [8]) and globally (2.3% overall hospital readmission in Wuhan [9], 4.4% overall hospital readmission in Madrid [10], 4.5% overall hospital readmission in South Korea [11], 7.1% 30-day hospital readmission in Turkey [12]). This could reflect the fact that some studies defined readmissions more strictly as COVID-related presentation or that some were confounded by a large number of patients remaining hospitalized during the study time period. Geographic differences, system function/capacity, and post-hospitalization follow-up and monitoring variability may also contribute. While much of the literature focuses on hospital readmission specifically, we have demonstrated that ED encounters also frequently occur after discharge. Around half of revisits in our cohort occurred in the ED, which is consistent with previous reports [13]. Several key findings from our data warrant additional attention. First, we have corroborated the finding from previous studies [10, 13] that shorter COVID-19 index hospital length of stay is associated with revisits after discharge. While the mechanism for this is not yet clear, it is possible either that there are unforeseen late-developing COVID-19 clinical changes that need to be better characterized and/or that system-level factors such as increased bed demand place strain on discharge decisions. Second, we have identified that discharge location is related to revisit rate with discharge to unstable housing over-represented in the revisit group and discharge to stable housing or an institutional setting under-represented. This supports the call for equitable approaches to care including both structural and individual responses to housing needs [14]. Finally, we highlight that reasons for admission are heterogeneous, especially in patients with revisits. Only around half of index admissions and revisits were directly related to COVID-19 for this population, but whether these presentations are truly unrelated or represent potential longer term sequelae of infection is undetermined. As more information is learned about the COVID-19 infection, it is possible that some issues (neurologic, hematologic, etc.) may be identified as complications of the infection itself though currently we are unable to characterize these findings as such. Though this study includes a relatively small sample size, we used a time period that spans the majority of the local outbreak and thus avoided the challenge of omitting a large proportion of patients who remain hospitalized. Further, while the local health care system experienced some strain, crisis standards of care were not implemented. Thus, we believe our findings are relevant and generalizable to hospital systems that continue to face a significant but not overwhelming COVID-19 burden. We also included patients from two hospitals that share a medical record. When comparing between hospitals, we did not identify a statistically significant difference in revisits, though there were some differences identified in demographics and outcomes that may reflect the different patient populations served (Supplemental Table 1). Additional exploration of hospital-based or geographic-based differences in revisits is an important area of future study. In conclusion, our results indicate that patients commonly access the healthcare system after index COVID-19 discharge and do so with a variety of presenting complaints. In addition, our findings suggest that attention to social needs such as housing security may be impactful in preventing readmissions and that additional investigation to better understand the impact of index length of stay is warranted. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 40 KB) Supplementary file2 (DOCX 16 KB)

          Related collections

          Most cited references11

          • Record: found
          • Abstract: found
          • Article: not found

          Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

          Research electronic data capture (REDCap) is a novel workflow methodology and software solution designed for rapid development and deployment of electronic data capture tools to support clinical and translational research. We present: (1) a brief description of the REDCap metadata-driven software toolset; (2) detail concerning the capture and use of study-related metadata from scientific research teams; (3) measures of impact for REDCap; (4) details concerning a consortium network of domestic and international institutions collaborating on the project; and (5) strengths and limitations of the REDCap system. REDCap is currently supporting 286 translational research projects in a growing collaborative network including 27 active partner institutions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

            There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              First Case of 2019 Novel Coronavirus in the United States

              Summary An outbreak of novel coronavirus (2019-nCoV) that began in Wuhan, China, has spread rapidly, with cases now confirmed in multiple countries. We report the first case of 2019-nCoV infection confirmed in the United States and describe the identification, diagnosis, clinical course, and management of the case, including the patient’s initial mild symptoms at presentation with progression to pneumonia on day 9 of illness. This case highlights the importance of close coordination between clinicians and public health authorities at the local, state, and federal levels, as well as the need for rapid dissemination of clinical information related to the care of patients with this emerging infection.
                Bookmark

                Author and article information

                Contributors
                mbann@uw.edu
                Journal
                Intern Emerg Med
                Intern Emerg Med
                Internal and Emergency Medicine
                Springer International Publishing (Cham )
                1828-0447
                1970-9366
                3 February 2021
                : 1-4
                Affiliations
                [1 ]GRID grid.34477.33, ISNI 0000000122986657, University of Washington School of Medicine, ; 1959 NE Pacific St, Seattle, WA 98195 USA
                [2 ]GRID grid.412618.8, ISNI 0000 0004 0433 5561, Division of GIM/Hospital Medicine, , Harborview Medical Center, ; 325 9th Avenue Box 359780, Seattle, WA 98104 USA
                Author information
                http://orcid.org/0000-0002-5893-950X
                Article
                2644
                10.1007/s11739-021-02644-9
                7857343
                33537919
                d080ef9c-6185-4ee9-97b6-4e539afc8561
                © Società Italiana di Medicina Interna (SIMI) 2021

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 17 November 2020
                : 13 January 2021
                Categories
                CE-Research Letter to the Editor

                Emergency medicine & Trauma
                Emergency medicine & Trauma

                Comments

                Comment on this article